Patients with chronic kidney disease (CKD) exhibit reduced exercise capacity, poor physical function and symptoms of fatigue. The mechanisms that contribute to this are not clearly defined but may involve reductions in mitochondrial function, mass and biogenesis. Here we report on the effect of non-dialysis dependent CKD (NDD-CKD) on mitochondrial mass and basal expression of transcription factors involved in mitochondrial biogenesis compared to a healthy control cohort (HC). In addition, we sought to investigate the effect of a 12-week exercise-training programme on these aspects of mitochondrial dysfunction in a NDD-CKD cohort.For the comparison between NDD-CKD and HC populations, skeletal muscle biopsies were collected from the vastus lateralis (VL) of n=16 non-dialysis dependent CKD patient's stage 3b-5 (NDD-CKD) and n=16 healthy controls matched for age, gender and physical activity (HC). To investigate the effect of exercise training, VL biopsies were collected from n=17 NDD-CKD patients before and after a 12-week exercise intervention that was comprised of aerobic exercise (AE) or a combination of aerobic exercise and resistance training (CE). Mitochondrial mass was analysed by citrate synthase activity and mitochondrial protein content by Porin expression, whilst the expression of transcription factors involved in mitochondrial biogenesis were quantified by real-time qPCR. NDD-CKD patients exhibited a significant reduction in mitochondrial mass when compared to HC, coupled to a reduction in PGC-1α, NRF-1, Nrf2, TFam, mfn2 and SOD1/2 gene expression. 12-weeks of exercise training resulted in a significant increase in PGC-1α expression in both groups, with no further changes seen across indicators of mitochondrial biogenesis. No significant changes in mitochondrial mass were observed in response to either exercise programme. NDD-CKD patients exhibit reduced skeletal muscle mitochondrial mass and gene expression of 1756 | WATSON eT Al. their contribution to the supervision of patient exercise training sessions.
| INTRODUCTION
Patients with chronic kidney disease (CKD) commonly exhibit skeletal muscle dysfunction, poor exercise tolerance, low exercise capacity, and physical function. [1] [2] [3] [4] This ultimately limits engagement in physical activity, reduces functional ability and is associated with high health and social care costs. These factors are also clinically important and are associated with increased risk of morbidity and mortality. [5] [6] [7] [8] The mechanisms underlying muscle dysfunction and poor exercise capacity are complicated, multi-factorial and are likely to vary between individuals. While interventions to address these problems are not yet common practice, we are beginning to understand more about the mechanisms likely to be responsible for muscle loss in CKD patients. For example, previous research has suggested a loss of muscle protein occurs primarily through an acceleration of protein degradation through the ubiquitin proteasome system 9 initiated by several factors including increased metabolic acidosis, 10,11 elevated myostatin signalling, 12 reduced insulin signalling, [13] [14] [15] [16] and inflammation. 17 Satellite cell dysfunction, which impairs the regenerative capacity of the muscle 15, 18 also contributes to this loss of muscle mass and associated function. 9 Finally, a role is emerging for aberrant microRNA expression in skeletal muscle wasting. 19 A change in microRNA expression has been seen in the skeletal muscle of mice with CKD 20 and research in CKD has focused on involvement of miR-29, miR-23a, and Mir-486. [20] [21] [22] Mitochondria are essential eukaryote organelles that produce the adenosine triphosphate (ATP) required for muscle contraction and cellular metabolism through oxidative phosphorylation (OXPHOS). Any disruption to mitochondrial number or function compromises ATP synthesis and is therefore a potential contributory mechanism to the poor exercise capacity and skeletal muscle function observed in these patients, recently been termed "acquired mitochondrial myopathy". 23 Such changes were originally observed as a slowing of postexercise phosphocreatine recovery using 31 P-magnetic resonance imaging ( 31 P-MRS) 24 and have been confirmed in skeletal muscle biopsy analysis from haemodialysis patients 25 and animal models of CKD. [26] [27] [28] Recently, Gamboa and colleagues 25 reported reduced mitochondrial density and mitochondria DNA (mtDNA) copy number within the skeletal muscle of haemodialysis patients compared to controls. However, there is as yet scarce evidence for mitochondrial dysfunction in CKD patients not on dialysis, or whether it can be restored by exercise training.
It is well established that regular exercise training in CKD patients improves physical functioning and exercise capacity. 29 However, not all studies have shown that CKD patients experience the expected increases in VO 2Peak following training. 30, 31 We also recently reported that 12 weeks of neither combined aerobic and resistance exercise, nor aerobic exercise (AE) alone, were able to significantly improve VO 2Peak in non-dialysis CKD stages 3b-5. 32 Improvements in VO 2Peak are primarily driven by increases in cardiac output and stroke volume, 33 however changes to mitochondrial volume and activity within skeletal muscle have also been shown to play a role. [33] [34] [35] An increased exercise capacity is linked to an improved ability to sustain ATP synthesis aerobically. Mitochondria are the key organelles that produce ATP through OXPHOS via utilization of carbohydrate and fat. Therefore, a greater mitochondrial content within skeletal muscle 36, 37 results in a greater capability to produce ATP aerobically, reducing reliance on anaerobic glycolysis thereby improving muscular endurance and exercise capacity. 34, 35 Mitochondrial biogenesis a tightly regulated process controlled in part by the activity of the transcriptional co-activator Peroxisome proliferator activated-receptor-γ co-activator 1α (PGC-1α). When activated PGC-1α translocates to the nucleus and initiates expression of downstream targets such as nuclear respiratory factor-1 (NRF1) and mitochondrial transcription factor A (TFam), which collectively over time, result in an increase in mitochondrial abundance. 38, 39 One possible explanation for the lack of an improvement in VO 2Peak with exercise training in CKD patients could be a failure of the exercise training to activate mechanisms of mitochondrial biogenesis, but this has not been investigated in these patients. transcription factors involved in mitochondrial biogenesis compared to HC. These reductions were not restored following 12-weeks of exercise training implying exercise resistance in this cohort. The reasons for this lack of improvement are currently unknown and require further investigation, as reversing the dysregulation of these processes in NDD-CKD may provide a therapeutic opportunity to improve muscle fatigue and dysfunction in this population. In the present study, we performed secondary analysis of a previously reported study 32 to explore the mechanisms behind the observed lack of an improvement in VO 2Peak . The aims were: (a) to determine whether reduced mitochondrial mass is apparent within skeletal muscle of CKD patients stage 3b-5 compared to healthy controls (HCs), and (b) to determine whether exercise training stimulates mitochondrial biogenesis and increases mitochondrial mass of skeletal muscle tissue.
| METHODS
Here we report data from two clinical studies: a comparison of mitochondrial mass between HCs and CKD non-dialysis stage 3b-5 from a cross-sectional observational study EXPLORE-CKD and a secondary analysis of a randomised control trial (RCT) of exercise training (ExTra-CKD), which has been previously described. 32 A CONSORT diagram describing the cohort from the RCT is shown in Figure 1 . Briefly, in the ExTra-CKD trial 54 patients with CKD stages 3b-5
were randomized to 12-wk CE or AE only, following a 6-wk run-in control period with outcome measures performed preand post-intervention. A subset of these patients consented to skeletal muscle biopsies from the vastus lateralis (VL) (AE, n = 10; CE n = 9). Approval for both studies was granted from the UK National Research Ethics Committee (nos. 13/ EM/0344; 15/EM/0467). All participants gave written informed consent, and the trial was conducted in accordance with the Declaration of Helsinki. The studies were registered with ISRCTN (no. 36489137; no. 18221837).
| Participants, muscle biopsy sampling and processing
Participants were matched for age, gender, and physical activity levels determined by the General Practice Physical Activity Questionnaire. All CKD patients were recruited from nephrology outpatient clinics at Leicester General Hospital, United Kingdom. Patients were excluded from undergoing a muscle biopsy if receiving warfarin or clopidogrel.
Participants in the observational EXPLORE-CKD study donated one muscle biopsy at a single time point. Patients in the ExTra-CKD RCT donated three muscle biopsies from the VL at the following time points: (a) baseline, (b) 24 hours after the first exercise bout (investigating the acute effect of exercise in the untrained state; untrained), and (c) 24 hours after the last exercise bout on completion of either 12 k AE or CE (investigating the acute effect of exercise in the trained state; trained). All patient biopsies were taken from the VL following an overnight fast using a micro biopsy technique. 40 All HC participants were recruited from orthopedic theater lists for the removal of benign intramuscular tumors and donated a single muscle biopsy. Samples were collected following an overnight fast using the open biopsy technique prior to resection of the tumor. Following dissection of any visible fat, samples were immediately placed in liquid nitrogen and stored until subsequent analysis.
| Quadriceps muscle size
Rectus femoris anatomical cross-sectional area (CSA) was determined using B-mode 2-D ultrasonography (Hitachi EUB-6500; probe frequency 7.5 MHz) as previously described 32, 41, 42 and has recently been validated against MRI 43 . Images were captured at the mid-point between the greater trochanter and the superior aspect of the patella on the midsagittal plane of the thigh. Three images were acquired with <10% variation and the mean CSA in cm 2 was recorded.
| Exercise training intervention
The ExTra-CKD study exercise intervention has been described in detail previously. 32 Briefly, patients attended supervised exercise training sessions three times per week for 12 weeks. The AE component consisted of a combination of treadmill, cycling, and rowing exercise. Patients aimed to undertake 30 minutes of exercise at a moderate intensity corresponding to 70%-80% heart rate maximum (obtained during a previous maximal exercise tolerance test) and a Borg rating of perceived exertion of 12-14 ("somewhat hard"). Patients randomized to CE carried out the same aerobic protocol with the addition of resistance exercise component performed on two of the three sessions each week, and consisted of leg extension and leg press exercisers performed on fixed-resistance machines (Technogym, Italy). The weight lifted was prescribed based upon results of a 5-repetition maximum test and was set to 70% estimated 1-repetition maximum (e-1RM) calculated using published equations. 44 Patients performed three sets of 12-15 repetitions with training loads increased when patients comfortably completed three sets with good form.
| Citrate synthase activity
Citrate synthase (CS) activity is considered a good marker of mitochondrial content. 45 CS activity was analyzed on skeletal muscle biopsies using the absorbance based CS activity assay (Abcam, UK, ab119692). Prior to experimental sample analysis, a skeletal muscle biopsy sample was processed and assayed using a serial dilution method in order to confirm the assays ability to detect change in a linear fashion at sample quantities in line with those of the experimental samples. Once confirmed, CS activity assays were conducted as per the manufacturer's instructions. Briefly, samples were homogenized in PBS at 4°C before the addition of extraction buffer and protein concentration determined using the Bio-Rad protein assay (BioRad, UK, 5000120), which was used to correct CS activity during analysis. The homogenate was then incubated for 3 hours. Wells were aspirated and activity reagent was added. Samples were then incubated for 5 minutes at room temperature and absorbance readings taken every 20 seconds for a further 25 minutes. Samples were assayed in triplicate with CS activity being calculated from the mean of the 3 values. CS activity (nmol·min −1 ·mg −1 ) was calculated and presented as previously described 46 .
| Quantitative RT-PCR
RNA was isolated from approximately 10 mg/wet weight muscle biopsy tissue using TRIzol (Fisher Scientific, UK, 15596018) and reversed transcribed to cDNA using an AMV reverse transcription system (Promega, Madison, WI, USA, A3500). Primers, probes, and internal controls for all genes were supplied as TaqMan gene expression assays (Applied Biosystems, Warrington, UK, 4331182) involved in mitochondrial biogenesis: Peroxisome proliferator activated-receptor gamma co-activator 1 alpha (PGC-1α): Hs00173304, NRF1: Hs00602161, Tfam: Hs00273372, mitofusin-2 (Mfn2): Hs00208382; Oxidative stress: Nuclear factor (erythroid-derived-2)-like 2 2 (Nrf2): Hs00975961, superoxide dismutase 1 (SOD1): Hs00533490, superoxide dismutase 2 (SOD2): Hs04260076; 18s Hs99999901 was used as an internal control which was determined to remain stable over the course of the intervention (data not shown). The Ct values from the target gene were normalized to 18s and expression levels calculated according to 2 −ΔΔCT method to determine fold changes.
| Western blotting
Lysates were prepared by homogenization of approximately 20 mg/wet weight muscle biopsy tissue in Tris buffer containing 0.5M EDTA (Sigma, UK, 798681), 40 nm EGTA (Sigma, UK, E3889), 10% Triton X-100 (Fisher Scientific, UK, 04807423), 0.1% betamercaptoethanol (Sigma, UK, M6250), supplemented with Phosphatase Inhibitor-3 cocktail (Sigma Aldrich, UK, P0044) and the following protease inhibitors Leupeptin (1 μg/mL) (Fisher Scientific, UK, 11462491), Pepstatin A (1 μg/mL) (Sigma, UK, P4265), Benzamidine (1 mM) (Sigma, UK, B6506), and PMSF (0.2 mM) (VWR, UK, 786-055). Lysates were rotated at 4°C for 90 minutes and centrifuged at 13 000g for 15 minutes. The resulting supernatant was collected and protein concentration determined using the Bio-Rad protein assay (BioRad, UK, 5000120). Lysates containing 30 μg protein were subjected to SDS-PAGE using 10% stain free gels (Bio-Rad, UK; OXPHOS subunits, 1610183) or 10%-12% poly-acrylamide gels (Porin) on a mini-protean tetra system (Bio-Rad, UK). Proteins were transferred onto nitrocellulose membranes (GE Healthcare, 10600002), blocked for 1 hour with tris-buffered saline with 5% (w/v) skimmed milk and 0.1% (v/v) tween-20 detergent. Membranes were incubated with the primary antibody overnight. Antibodies to determine porin (Santa Cruz Biotechnology, USA, SC-390996) were used at 1:1000 dilution, β-actin at 1:2000 dilution (Abcam, USA, ab227). Abundance of mitochondrial electron transport chain (ETC) subunits was determined using OXPHOS antibody cocktail (Abcam, USA, ab110413) at 1:500 dilution. Following washing, membranes were incubated with species specific horse radish peroxides conjugated secondary antibodies (Dako, anti-mouse, P0260) and visualized using EZ-chemiluminescence detection kit (Geneflow, Lichfield, UK, K1-0172) and band intensity captured using ChemiDoc touch instrument (BioRad, UK) and quantified using Image Lab Software (BioRad, UK).
| Statistical analysis
Data were presented as mean ± standard deviation unless otherwise stated. All data were tested for normality using the Shapiro-Wilk test. Non-normally distributed data were either log-transformed prior to analysis or a nonparametric equivalent was used as appropriate. Comparisons between CKD patients and HCs were made using independent samples t tests or Mann-Whitney U tests as appropriate. Effect sizes were estimated using cohens d (d; interpreted small ≥0.20, medium ≥0.50, and large ≥0.80). To determine the effect of exercise over time and between groups a two-way repeated measures ANOVA was used (time × trial) with predetermined pairwise comparisons (baseline vs untrained [ie, 24 hours after first exercise session], baseline vs trained [ie, 24 hours after last exercise session], untrained vs trained). Effect sizes were calculated using the partial eta squared statistic (ηp 2 ; interpreted as small = 0.04, medium = 0.06, and large = 0.14). Statistical analysis was carried out using IBM SPSS 25 software (IBM, Chicago, IL). Statistical significance was accepted as P < .05.
| RESULTS

| Baseline Characteristics
Individual characteristics of patients with CKD and matched HCs that were included in the comparative analysis can be found in Table 1 . Patient characteristics of those who took part in the RCT can be found in Table 2 . From the consented cohort, there was insufficient material from two individuals in the CE cohort and thus analysis was performed on the remaining sample set (n = 7).
| Evidence of reduced mitochondrial mass in skeletal muscle of CKD patients compared to HCs
Skeletal muscle CS activity was 46% lower in the CKD patients compared to the control group (Figure 2A , P = .006; d = 0.99). Porin/β-actin ratio was also substantially reduced by 86% in CKD patients compared to the HCs (Figure 2B ; P < .001; d = 2.10), which effect size analysis considered both to be large effects. In contrast, significant increases were noted in CKD patients compared to HCs in regards to the abundance 
| Exercise training fails to increase mitochondrial mass, OXPHOS complex abundance, or expression of transcription factors involved in mitochondrial biogenesis and oxidative stress
The ability of acute exercise or chronic exercise training to stimulate increases in mitochondrial mass was investigated in skeletal muscle biopsies donated from patients taking part in the ExTra-CKD 12-wk exercise training study. 32 No change was observed in either CS activity (P = .11, ηp 2 = 0.05) or porin/β-actin ratios at any time point in either group (P = .15; ηp 2 = 0.01). There was also no change seen from baseline in protein abundance of any mitochondrial ETC complex subunits post exercise, 24 hours after first training session, or 24 hours after the last training session, nor were there any differences observed between the two alternative exercise modalities employed (Figure 4) .
No change was seen in the expression of NRF-1 (P = .83; ηp 2 = 0.01), TFam (P = .24; ηp 2 = 0.01), or Mfn2 (P = .12; ηp 2 = 0.17) over time in either training group ( Figure 5) . In response to an unaccustomed bout of exercise, the change in PGC-1α expression from baseline was seen to differ, albeit nonsignificantly, between groups (P = .27, d = 0.50); the AE group exhibited a 1.6-fold decrease in expression, while the CE group exhibited a modest 1.1-fold increase in expression. However, 24 hours after the last training session, the expression of PGC-1α was significantly elevated above baseline in both groups compared to the response made prior to training (P = .04; AE = 1.7-fold increase d = 0.54, CE = 1.7-fold increase d = 0.55; Figure 5 ), a medium sized effect in both groups.
The mRNA expression of Nrf2, SOD1, and SOD2 were measured as indicators of the cellular antioxidant response to exercise within skeletal muscle. In both training groups there was a significant increase in Nrf2 and SOD2 expression in response to exercise prior to training (P = .006, d = 0.46; P = .003 d = 0.49 respectively), responses that were then both reduced following training (P = .057, d = 0.84; P = .01 d = 0.53 respectively).
Although just falling short of significance, the reduction in Nrf2 expression following training was deemed to be a medium sized effect. No statistical differences were seen between exercise modalities. This suggests that when unaccustomed, both AE and CE activate anti-oxidant defense mechanisms that are not required following training. No change in SOD1 expression was seen following exercise in either group (P = .48; ηp 2 = 0.06; Figure 6 ).
| DISCUSSION
In this study, we have shown that patients with CKD (as early as stage 3b) display reductions in skeletal muscle mitochondrial mass compared to healthy matched counterparts, coupled to a reduction in the gene expression of transcription factors involved in mitochondrial biogenesis. Furthermore, for the first time, we have shown that 12 weeks of exercise training does not reverse this deficit despite increases in PGC1-α transcription in this population. Mitochondria are key components of muscle health and mitochondrial dysfunction has been implicated as a driver of muscle loss during ageing and also in other disease states. [47] [48] [49] [50] Mitochondrial myopathy has been suggested to play an important role in the skeletal muscle dysfunction, and poor physical functioning common in patients with CKD. 23 Until now, there are limited data regarding mitochondrial biogenesis within skeletal muscle of pre-dialysis CKD patients, or in the ability of exercise to stimulate increases in mitochondrial mass and oxidative capacity.
Studies of mitochondria isolated from peripheral blood mononuclear cells (PBMCs) suggest that alterations in mitochondrial function are present in patients with end-stage CKD, 25, 51, 52 however, this does not accurately reflect skeletal muscle mitochondrial function/mass 53 . There is very little evidence regarding skeletal muscle mitochondrial function or content in patients at earlier stages of CKD, not yet requiring dialysis. To our knowledge there have only been two previous reports. Gamboa and colleagues 25 reported that the skeletal muscle of haemodialysis patients exhibited reduced mitochondrial density, mtDNA copy number and increased BNIP3 suggesting an increase in mitophagy compared to HCs, but no alteration in PGC-1α protein expression. Roshanravan and colleagues 54 reported an uncoupling of mitochondria within skeletal muscle determined using 31 P-MRS. There is considerable evidence for impaired skeletal muscle mitochondrial function in CKD from animal models. These studies have reported a reduction in complex IV enzyme activity and mitochondrial respiratory capacity, 26 a reduction in mitochondrial mass, [26] [27] [28] an increase in mitophagy, 28, 55 and a reduction in PGC-1α mRNA expression. 28, 55, 56 In line with previous results from animal models of CKD, 26, 28 we have shown that patients with moderate to severe CKD stage 3b-5 display a 46% reduction in skeletal muscle CS activity and a 86% decrease in the porin/β-actin ratio suggesting a substantial reduction in mitochondrial mass compared to healthy matched controls. We have also shown a significant reduction in the expression of transcription factors involved in mitochondrial biogenesis, (PGC-1α, NRF-1, TFam, and Mfn2), and the oxidative stress response (Nrf2, SOD1, and SOD2). PGC-1α regulates the expression of a number of transcription factors including NRF-1 and TFam, that together result in a coordinated increase in the expression of mitochondrial proteins. A reduction in the expression of these transcription factors may explain the reduced mitochondrial density observed here, and ultimately the poor exercise capacity and physical functioning seen in these patients. The potential drivers of such a decrease in aspects of mitochondrial function in CKD are beyond the scope of this report and warrant further investigation, but are likely to involve inflammation and oxidative stress, 28 ageing, 23 and physical inactivity. 38 Interestingly, these defects were seen alongside significant increases in three of the five ETC complexes in the CKD patients. This might be a posttranslational compensatory increase in an attempt to rescue these defects and maintain respiration rates. This data certainly indicates important changes have occurred to the mitochondrial proteome in these patients with pre-dialysis CKD, which warrants further investigation.
Mitochondrial biogenesis encompasses the synthesis of new mitochondrial organelle components that are required to drive the improvements in mitochondrial function conferred by exercise training. However, mitochondrial biogenesis has previously been reported to be blunted by ageing and physical inactivity, both of which are associated with CKD. Traditionally, AE training is well documented to stimulate mitochondrial biogenesis, driven by energy stresses created during the exercise bout 38 and resulting in increased exercise capacity and tolerance. Recently, high-load resistance training has also been shown to be capable of stimulating this process. 57 Furthermore, 8 weeks of CE in older adults resulted in greater improvements in mitochondrial OXPHOS and biogenesis markers than either intervention alone. 58 The ability of any form of exercise to stimulate mitochondrial biogenesis within skeletal muscle in patients with CKD has not been well studied. Balakrishnan and colleagues 59 previously reported that 12 weeks of resistance training in pre-dialysis patients resulted in a significant increase in mtDNA copy number compared to an attention control group, though how this was related to markers of mitochondrial biogenesis was not investigated. Uraemic animal models of muscle overload have also shown increased in mtDNA copy number and F I G U R E 6 Skeletal muscle anti-oxidant transcriptional response to exercise is not altered following 12 weeks of AE or CE training. Data is presented as mean ± 95% confidence intervals. A-C, Real time PCR data presented as 2 −ΔΔCT relative to baseline. **Denotes P < .01 vs baseline and vs untrained a reversal of the CKD induced decrease in PGC-1α, TFam, and Mfn2 mRNA expression in the overloaded muscle. 55 Finally, exercise-mediated improvements in CS activity were reported to be reduced in uraemic rats. 60 Changes in PGC-1α mRNA expression in response to exercise are relatively short lived, with expression levels returning to baseline within 24 hours. 61 It is unlikely therefore, that from the time points we have investigated here, we are able to draw any conclusions regarding the ability of exercise to stimulate changes in mRNA expression, but instead can infer effects of training on the basal levels of expression of these transcription factors. Following 12 weeks of both CE and AE we report a significant 1.7-fold increase in PGC-1α mRNA expression in both groups. Interestingly, there was no change in the expression of Mfn2, NRF-1, or TFam, well defined targets of PGC-1α and no detectable increase in OXPHOS complex abundance, CS activity, or in porin/βactin ratios, suggesting there was no detectable increase in mitochondrial mass following exercise training. PGC-1α is posttranscriptionally regulated; and is thought to be phosphorylated by AMPK and P38 MAPK and deacetylated by SIRT1, 62, 63 increasing PGC-1α activity and its translation to the nucleus. Again, due to the time points the biopsy samples were collected, it was not possible to investigate the activation of these regulators of PGC-1α following exercise. It is possible that despite an increase in mRNA transcript levels, exercise failed to activate AMPK, P38 MAPK, and SIRT1 reducing PGC-1α translocation to the nucleus and subsequent expression of downstream targets. This investigation of the acute response to exercise warrants future investigation. The findings presented here are in contrast to the previous studies described above, but reflect the physiology observed in these patients, where neither 12 weeks of AE or CE resulted in a significant increase in VO 2Peak . 32 However, it is important to keep in mind that this study was not powered to detect improvements in VO 2Peak and may simply reflect an underpowered data set. The reason for the difference with previous studies is hard to determine and to our knowledge the effect of these specific exercise programs on these aspects of mitochondrial function have not been studied previously in these patients. CKD is a complex, often comorbid condition, which is further compounded by ageing. This makes it hard to compare these patients to other clinical populations, such as the elderly. However, a similar finding has been reported in patients with type 2 diabetes mellitus, 64 where 12 weeks of AE failed to stimulate an increase in either PGC-1α or Mfn2 mRNA expression and ultimately VO 2Peak .
It is well documented that CKD patients experience high levels of systemic oxidative stress, 52, 65 and evidence suggests a greater degree of oxidative stress induced damage to the mitochondria is apparent in patients compared to their healthy counterparts. 66 Dysfunctional mitochondria are a major source of free radicals, 67 which may result in a vicious cyclic enhancement of oxidative stress leading to further damage to these organelles. Exercise has been shown to induce antioxidant mechanisms in other disease states, 68 but little is known if this also is the case in CKD. We hypothesised that CKD patients would exhibit an up-regulation of basal Nrf2 and SOD1/2 mRNA expression in comparison to the HC group indicating activation of antioxidant programs. However, this was not the case, and indeed the opposite was observed, where these were significantly suppressed in the CKD cohort. The implication of this is unknown and warrants further mechanistic investigation, although it could be hypothesised in light of the current data set that patients are unable to respond to oxidative stress within skeletal muscle as effectively as healthy individuals, which may then have further implications for mitochondrial function. These mechanisms were up-regulated in response to an unaccustomed bout of both AE and CE, which is commonly reported, 69, 70 but the same acute response was not seen following regular training.
An obvious limitation to the present study was our inability to directly measure mitochondrial function, instead inferring changes in mitochondrial mass from established proxy markers. 45 Further to this, although the current study did not have a traditional inactive control group, it is in our experience that patients consent to studies of this nature due to the potential benefits that could be achieved. This, plus the addition of advocating inactivity being unethical, meant that this was not possible in the current study. For findings to be confirmed for clinical prescription, an inactive control group would be required as part of a large scale multi-centre RCT. It would have been interesting to determine if there was any change in muscle fiber phenotype following exercise training, which may also heavily influence changes in oxidative capacity, but this analysis was not performed here. Further to the determination of muscle phenotype, analysis of biopsy samples from other muscles within the quadriceps muscle group, such as the biceps femoris, would have been of great interest. It can be assumed that the mixed AE modalities used in the current study, though a better representative of an implementable exercise prescription, would provide differing levels of stress to different contractile contributors. As such, future investigations should look to control this through careful consideration of targeted exercise modalities or by sampling from multiple localized sites in order to compare adaptations between exercise modalities across different contractile contributors in this population. Finally, while the patients and controls were matched for physical activity levels, this was done using subjective measures. This is not as accurate as accelerometry data, which was not available from this study.
In summary, we have shown here that CKD results in a reduction of skeletal muscle mitochondrial mass and suppresses mRNA expression of transcription factors involved in mitochondrial biogenesis. This effect was not restored following 12 weeks of either AE or CE. The mechanisms that drive this suppression and a closer investigation of the ability of exercise to activate mitochondrial biogenesis warrants further investigation as this may indicate a target of potential intervention to improve exercise capacity and physical function in these patients.
